Going to Europe-Hunan Warrant Attended CPHI Milan 2024 to Show International Competitiveness

By HWC Pharma | Updated: 2024-10-14 09:39:31

【CPHI Milan Overview】

From 8th to 10th October, the highly anticipated Chemical Pharmaceutical Ingredient Worldwide Exhibition (CPHI Milan 2024) was held at the International Exhibition Center in Milan, Italy. As the world's largest pharmaceutical industry professional exhibition, CPHI has been actively participated in and widely recognized by the world's pharmaceutical raw material industry practitioners, and has become an annual event for the pharmaceutical industry.

 

In this exhibition, Hunan Warrant built an exhibition stall of 36 square meters for the first time in the overseas exhibition, team members and international customers get together to discuss the opportunity of cooperation and the development of new blueprints, new ideas. At the same time, the company is on the same stage with the international top pharmaceutical enterprises and R&D institutions, showing the international competitiveness in the R&D, production and sales of APIs, and enhancing the international influence of the company.

【Hunan Warrant Introduction】

As a listed company on the science and technology innovation board featuring the integration of raw materials and formulations, API is an important business segment of Hunan Warrant. The participating team members met with pharmaceutical companies and customer representatives from all over the world to discuss the development situation of the global pharmaceutical industry, pharmaceutical industry policies, etc., and shared the latest progress and innovation results of the company in various aspects of research and development, production and quality control.

The person in charge of the company's exhibition introduced that the wholly-owned subsidiary Hunan Warrant Chiral Pharmaceutical Co., Ltd. possesses the leading capabilities in chemical process R&D and industrialization, accordingly equipped with comprehensive management system, EHS management system and good product service capabilities, and the facility has passed GMP compliance inspection in China and South Korea. And now is preparing for official certification of US FDA, Japan PMDA, EU authorities, etc., a number of products have been marketed in multiple countries and regions worldwide, and the market share of the major products continue to expand.

 

From the data point of view, in 2023, the company's revenue of APIs and intermediates was 287 million RMB, an increase of 39.04%. In the first half of 2024, the company's revenue of APIs and intermediates was 176 million RMB, an increase of 18.69%. In terms of products, the company has 59 kinds of characteristic chemical APIs, of which 47 are registered with the status of "A". These kinds will further enrich the company's product line and enhance the company's core competitiveness. In addition, the company has 91 research projects, including 9 international registered projects.

 

In the future, the company will further expand the market share of superior APIs, actively carry out the international registration and association of APIs, and promote the export of APIs.